公开(公告)号：WO00034446A1

公开(公告)日：2000-06-15

申请号：PCT/AU1999/001083

申请日：1999-12-06

IPC: A61K35/14 ,  A61L2/00 ,  A61P31/12 ,  C12N7/06 ,  A61L2/16

CPC classification number: C12N7/00 ,  A61K35/16 ,  A61L2/0011 ,  A61L2/0017 ,  A61L2/0088 ,  A61L2/08 ,  A61L2/18 ,  C12N2770/32263 ,  Y02A50/463

Abstract: The present invention provides a method for inactivating a virus in solution. The method comprises adding to a solution, suspected of containing virus, a first agent which increases the permeability of the viral capsid, and a second agent which interacts with the viral nucleic acids. The first agent allows the second agent to penetrate the viral capsid and interact with the viral nucleic acids.

Abstract translation: 本发明提供了一种在溶液中灭活病毒的方法。 该方法包括向疑似含有病毒的溶液中加入增加病毒衣壳的通透性的第一药剂和与病毒核酸相互作用的第二药剂。 第一种药剂允许第二种药剂穿透病毒衣壳并与病毒核酸相互作用。

公开(公告)号：WO00000225A1

公开(公告)日：2000-01-06

申请号：PCT/US1999/014788

申请日：1999-06-30

IPC: F26B3/08 ,  A01N1/00 ,  A61L2/00 ,  A61L2/04 ,  A61L2/20 ,  C12N1/00 ,  C12N7/06 ,  F26B3/12 ,  A61L2/02 ,  A61L2/06

CPC classification number: F26B3/12 ,  A61L2/0094 ,  A61L2/20

Abstract: The invention relates to treating samples to reduce, substantially reduce, inactivate, or eliminate adventitious agents or toxins present in the sample of interest. These ends are accomplished by drying or substantially drying the sample.

Abstract translation: 本发明涉及处理样品以减少，基本上减少，灭活或消除目的样品中存在的外来物质或毒素。 通过干燥或基本干燥样品来实现这些目的。

公开(公告)号：WO99043790A1

公开(公告)日：1999-09-02

申请号：PCT/US1999/004186

申请日：1999-02-26

IPC: C12M1/42 ,  A61L2/00 ,  B01F11/00 ,  B01F13/00 ,  C12N7/04 ,  C12N7/06 ,  C12N13/00 ,  C12M3/00

CPC classification number: A61L2/0011 ,  A61L2/08 ,  B01F11/0065 ,  B01F13/0001 ,  B01F13/001 ,  C12N7/04

Abstract: An apparatus and method for illuminating a fluid having photosensitive material therein comprising a surface and a roller separated from the surface by a space. The space is adapted to receive a flexible container therein. The flexible container on the surface contacts the roller and the surface for translation through the space. A light source is adapted to transmit light to the space to illuminate the fluid and react with the photosensitive material as the flexible container translates through the space.

Abstract translation: 一种用于照亮其中具有感光材料的流体的装置和方法，其中包括一个表面和一个通过一个空间从该表面分离的辊。 该空间适于在其中容纳柔性容器。 表面上的柔性容器接触辊子和表面，以便通过该空间进行平移。 光源适于将光传输到空间以照亮流体，并且随着柔性容器翻转通过空间而与感光材料反应。

公开(公告)号：WO99033484A1

公开(公告)日：1999-07-08

申请号：PCT/US1998/025208

申请日：1998-12-07

IPC: A61K38/16 ,  A61K35/14 ,  A61K39/395 ,  A61P43/00 ,  C07K16/00 ,  C07K16/06 ,  A61K38/12 ,  A23J1/00 ,  C12N7/04 ,  C12N7/06

CPC classification number: C07K16/065

Abstract: A process for producing an intravenously-administrable gamma globulin solution substantially free of contaminating viruses by heat treating for viral inactivation and fractionating an impure gamma globulin solution and then treating the purified gamma globulin with a solvent-detergent for further viral inactivation.

Abstract translation: 用于通过热处理用于病毒灭活并分级分离不纯的γ球蛋白溶液，然后用溶剂洗涤剂处理纯化的γ球蛋白以进一步病毒灭活来生产基本上不含污染病毒的静脉内施用的γ球蛋白溶液的方法。

公开(公告)号：WO2022130732A1

公开(公告)日：2022-06-23

申请号：PCT/JP2021/036078

申请日：2021-09-30

Applicant: 中村　正一 ,  日本エー・シー・ピー株式会社

Inventor： 中村　正一 NAKAMURA Shoichi

IPC: A01N65/03 ,  A01P1/00 ,  A23G3/34 ,  A23G3/42 ,  A23G3/48 ,  A23G4/10 ,  A23L2/52 ,  A23L17/60 ,  A23L33/10 ,  A23L33/105 ,  A23L33/16 ,  A61K8/9711 ,  A61K8/99 ,  A61K9/20 ,  A61K31/194 ,  A61K31/7012 ,  A61K31/715 ,  A61K31/734 ,  A61K31/737 ,  A61K33/10 ,  A61K33/18 ,  A61K36/02 ,  A61K36/03 ,  A61K47/02 ,  A61K47/12 ,  A61K47/26 ,  A61K47/36 ,  A61P1/02 ,  A61P17/00 ,  A61P31/12 ,  A61P43/00 ,  A61Q11/00 ,  A61Q11/02 ,  A61Q19/10 ,  C12N7/06

Abstract: 海藻類及びその抽出物による口腔用、鼻孔用又は咽喉用の衛生用品を提供する。　昆布、ワカメ、アオサ等の海藻類及び／又はその抽出物から成る、ＳＡＲＳ－ＣｏＶ－２、インフルエンザウイルス、ノロウイルス等を含むウイルスに対する不活性化作用と共に、大腸菌、黄色ブドウ球菌を含む細菌に対する殺菌作用を有する、洗口液、口腔用、鼻腔用又は咽喉用の洗浄剤を含む口腔用又は鼻孔用の衛生用品。ここで、前記口腔用衛生用品は、口内に一定時間留まって唾液の分泌を促す喉飴、チューイングガム、おしゃぶり食品を含む。

公开(公告)号：WO2021252954A2

公开(公告)日：2021-12-16

申请号：PCT/US2021/037090

申请日：2021-06-11

Applicant: SCHOSSAU, Tom M.

Inventor： KURUP, Shree K. ,  SCHOSSAU, Jorden

IPC: A61K39/12 ,  A61K39/215 ,  A61P31/12 ,  C12N7/04 ,  C12N7/06 ,  A61K2039/5252 ,  A61P31/14 ,  C12N2770/20034

Abstract: Vaccine based on ethanol inactivated pathogens, or part thereof, are described herein. Also disclosed are certain vaccines for treating COVID-19 or other coronavirus related diseases is created by deactivating the genome, genetic material or RNA encapsulated within the shell of virus without eliminating the spikes or spike protein, which both attaches the virus to a host cell and is detected by the body to produce antibodies. Treatment of an active coronavirus with a material such as an effective amount of ethanol will both penetrate the shell and deactivate the genetic material which causes the disease, for preparation of a vaccine.

公开(公告)号：WO2019011900A1

公开(公告)日：2019-01-17

申请号：PCT/EP2018/068628

申请日：2018-07-10

Applicant: BAXALTA INCORPORATED ,  BAXALTA GMBH

Inventor： HAMMERSCHMIDT, Nikolaus ,  SENCAR, Jure ,  JUNGBAUER, Alois ,  MARTINS, Duarte Lima

IPC: A61L2/00 ,  B01F5/06 ,  C07K1/36 ,  C12N7/06

Abstract: The present invention relates a method for incubating liquids, to a method for preparing a biopharmaceutical drug, and to a device for the preparation of a biopharmaceutical drug.

公开(公告)号：WO2017132059A1

公开(公告)日：2017-08-03

申请号：PCT/US2017/014267

申请日：2017-01-20

Applicant: ELI LILLY AND COMPANY

Inventor： DIAZ, Leyla ,  WU, Stephen

IPC: C07K14/08 ,  C12N7/06

CPC classification number: C12N7/00 ,  C12N2760/16134 ,  C12N2760/16151 ,  C12N2770/10051

Abstract: The present invention relates to vaccines containing enveloped viruses whose envelopes have been depleted of lipids using methyl β-cyclodextrin (MBCD). Delipidation of enveloped viruses in a two-step process abolishes the infectivity of those viruses, which allows delipidated viruses to be used safely in vaccines. Use of MBCD to deplete lipids such as cholesterol, in contrast to other methods, results in viruses with less than 20% of the cholesterol of an untreated virus but such delipidated viruses retain at least 85% of the protein content of an untreated virus. Delipidation by MBCD also preserves the immunogenicity of the viral proteins. The present invention of using MBCD treatment in a two-step process to delipidate enveloped virus represents a new alternative for generation of inactivated viruses which are incorporated into effective vaccines.

Abstract translation: 本发明涉及含有包膜病毒的疫苗，其使用甲基β-环糊精（MBCD）其包膜已经被脂类耗尽。 以两步法脱脂包膜病毒可以消除这些病毒的传染性，从而使脱脂病毒在疫苗中安全使用。 与其他方法相比，使用MBCD消耗脂质如胆固醇导致病毒含有低于未处理病毒胆固醇的20％，但这种去脂质病毒保留未处理病毒蛋白质含量的至少85％。 MBCD脱脂也保留了病毒蛋白的免疫原性。 本发明在两步法中使用MBCD处理来脱脂包膜病毒代表了用于产生灭活病毒的新选择，所述灭活病毒被并入有效疫苗中。

公开(公告)号：WO2016007955A1

公开(公告)日：2016-01-14

申请号：PCT/US2015040181

申请日：2015-07-13

Applicant: MERIAL INC

Inventor： ANBALAGAN SRIVISHNUPRIYA ,  COLLIN EMILY ,  HAUSE BENJAMIN MATTHEW

IPC: A61K39/225 ,  C07K14/08 ,  C12N7/06

CPC classification number: A61K39/215 ,  A61K39/225 ,  A61K2039/5252 ,  C12N7/00 ,  C12N2770/18034 ,  C12N2770/18071 ,  C12N2770/20021 ,  C12N2770/20034

Abstract: The present invention encompasses porcine epidemic diarrhea virus (PEDV) vaccines or compositions. The vaccine or composition may be a vaccine or composition containing inactivated PEDV. The invention also encompasses epitopes or immunogens which can be used to protect porcine animals against PEDV.

Abstract translation: 本发明包括猪流行性腹泻病毒（PEDV）疫苗或组合物。 疫苗或组合物可以是含有灭活的PEDV的疫苗或组合物。 本发明还包括可用于保护猪动物免受PEDV的表位或免疫原。

公开(公告)号：WO2008026225A3

公开(公告)日：2008-09-25

申请号：PCT/IN2007000383

申请日：2007-08-31

Applicant: BHARAT BIOTECH INT LTD ,  ELLA KRISHNA MURTHY ,  SUMATHY KANDASWAMY ,  PYDIGUMMALA JAYA SHEELA ,  HEDGE NAGENDRA R

Inventor： ELLA KRISHNA MURTHY ,  SUMATHY KANDASWAMY ,  PYDIGUMMALA JAYA SHEELA ,  HEDGE NAGENDRA R

IPC: A61K39/12 ,  C07K14/18 ,  C12N7/02 ,  C12N7/06

CPC classification number: C07K14/005 ,  A61K39/12 ,  A61K2039/5252 ,  C12N7/00 ,  C12N2710/14143 ,  C12N2770/36122 ,  C12N2770/36134 ,  C12N2770/36151 ,  C12N2770/36163

Abstract: The present invention relates to vaccine formulation capable of eliciting protective immune response against Chikungunya virus infection in humans and other mammalian hosts. The immunogenic formulation comprises purified inactivated Chikungunya virus in a stable formulation. Methods of propagation and purification of the virus are discussed. The inactivated virus formulation is non-infectious, immunogenic and elicits protective immune response in mammalian host. The immunogenic composition is formulated for in vivo administration to humans. The invention also discusses the strategy of developing a subunit vaccine using the recombinant viral proteins as antigens for immunization. The recombinant virus antigens that are potentially immunogenic can be used in diagnosing for the presence of the virus.

Abstract translation: 本发明涉及能够在人和其他哺乳动物宿主中引发针对基孔肯雅病毒感染的保护性免疫应答的疫苗制剂。 免疫原性制剂包含稳定制剂中的纯化的灭活基孔肯雅病毒。 讨论了病毒繁殖和纯化的方法。 灭活的病毒制剂是非感染性的，免疫原性的并在哺乳动物宿主中引起保护性免疫应答。 配制免疫原性组合物用于体内施用给人。 本发明还讨论了使用重组病毒蛋白作为免疫抗原开发亚单位疫苗的策略。 具有潜在免疫原性的重组病毒抗原可用于诊断病毒的存在。